The National Prescribing Service Limited (Australia) made an independent evaluation on the role of desvenlafaxine (Pristiq) for the treatment of major depressive disorder.


In an article published in Annals of Pharmacotherapy.  Desvenlafaxine: Another "Me Too" Drug?, the authors conclude:

“With the overall similarity between these 2 drugs and the potential lack of cost savings, the need for desvenlafaxine and its ultimate utility in treating major depressive disorder appears to be insignificant.”

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos